AstraZeneca, one of the world’s leading pharmaceutical companies, has reinforced its commitment to the Chinese market with a substantial investment. Last year, the British biopharmaceutical giant invested $700 million to establish an inhaled medicines manufacturing site in Qingdao City, Shandong Province.
Leon Wang, AstraZeneca’s executive vice president, expressed the company’s dedication to innovation in China during an interview with CGTN host Lincoln Humphries. He stated that “China is the best location for innovation,” emphasizing the strategic importance of the country’s role in AstraZeneca’s global operations.
The investment in Qingdao not only signifies AstraZeneca’s confidence in China’s potential for pharmaceutical innovation but also underscores the company’s intention to bolster its presence in the region. The new manufacturing site is expected to enhance the production capacity for inhaled medicines, catering to growing healthcare needs.
Reference(s):
cgtn.com
